Humana (HUM) Price Target Cut to $327.00 by Analysts at Barclays

Humana (NYSE:HUM) had its price objective cut by research analysts at Barclays from $351.00 to $327.00 in a research note issued to investors on Wednesday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the insurance provider’s stock. Barclays‘s price objective suggests a potential upside of 40.41% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the company. ValuEngine cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Citigroup decreased their price objective on Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a report on Thursday, February 7th. Credit Suisse Group decreased their price objective on Humana from $390.00 to $352.00 and set an “outperform” rating on the stock in a report on Thursday, February 7th. Finally, Stephens assumed coverage on Humana in a report on Monday, January 14th. They set an “overweight” rating and a $336.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $353.72.

Shares of NYSE:HUM opened at $232.89 on Wednesday. The firm has a market cap of $31.89 billion, a price-to-earnings ratio of 16.01, a P/E/G ratio of 1.05 and a beta of 0.93. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.68 and a current ratio of 1.68. Humana has a one year low of $225.65 and a one year high of $355.88.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 6th. The insurance provider reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.12. The firm had revenue of $14.17 billion for the quarter, compared to analysts’ expectations of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. Humana’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.06 EPS. As a group, equities research analysts forecast that Humana will post 17.5 earnings per share for the current year.

In other Humana news, insider Roy A. Beveridge sold 8,278 shares of Humana stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the transaction, the insider now directly owns 12,409 shares in the company, valued at approximately $3,811,548.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher H. Hunter sold 15,586 shares of Humana stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the transaction, the insider now owns 28,100 shares in the company, valued at $8,577,244. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Moody National Bank Trust Division purchased a new position in shares of Humana during the 4th quarter valued at $30,000. We Are One Seven LLC purchased a new position in shares of Humana during the 4th quarter valued at $31,000. Proficio Capital Partners LLC grew its holdings in shares of Humana by 81.4% during the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 48 shares in the last quarter. Exane Asset Management purchased a new position in shares of Humana during the 4th quarter valued at $43,000. Finally, Sontag Advisory LLC purchased a new position in shares of Humana during the 4th quarter valued at $47,000. Hedge funds and other institutional investors own 94.52% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Leveraged Buyout (LBO)

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.